Compare FMNB & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | SLDB |
|---|---|---|
| Founded | 1887 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.3M | 498.6M |
| IPO Year | 2010 | 2017 |
| Metric | FMNB | SLDB |
|---|---|---|
| Price | $13.84 | $8.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $14.33 | ★ $16.36 |
| AVG Volume (30 Days) | 332.5K | ★ 1.0M |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | 18.85 | ★ 34.97 |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $279,922,000.00 | $8,094,000.00 |
| Revenue This Year | $52.63 | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | $9.58 | ★ N/A |
| Revenue Growth | ★ 3.89 | N/A |
| 52 Week Low | $12.23 | $2.51 |
| 52 Week High | $15.50 | $8.87 |
| Indicator | FMNB | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 59.63 |
| Support Level | $12.99 | $5.16 |
| Resistance Level | $14.36 | $8.22 |
| Average True Range (ATR) | 0.27 | 0.57 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 63.86 | 73.40 |
Farmers National Banc Corp is a one-bank holding company engaged in financial activities, including securities underwriting and dealing, insurance agency and underwriting activities, and merchant banking activities. It operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The company has two operating segments of business; the Bank segment, and the Trust segment, out of which the majority of the company's revenue is derived from the bank segment.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.